Sentences with phrase «hiv vaccine design»

Data from a study done 20 years ago on maternal - infant HIV transmission give clues that could lead to better HIV vaccine design

A critical implication of this work for the field of HIV vaccine design is the observation that the most potent and broad individual anti-HIV VHH, J3, was elicited in response to the gp140 immunogens used.

«Uncovering the process by which neutralizing antibodies develop is critical to HIV vaccine design,» said Elise Landais, Senior Research Scientist with IAVI and lead author of the study.

«New findings to help HIV scientists establish «template» for potent antibodies: Natural - infection studies in Africa and India continue to inform HIV vaccine design.»

«Research focused on basic B cell biology is the foundation for the development of an HIV vaccine designed to drive the B cell arm of the immune response.»

Not exact matches

These findings provide insights for the design of vaccines that can «kick - start» and then shape the maturation of broadly neutralizing antibodies in HIV uninfected individuals, to provide protection from HIV exposure.

«New study has important implications for the design of a protective HIV vaccine.»

The study has important implications for the design of a protective HIV vaccine.

Using the findings from this study, the team has designed vaccine immunogens to selectively trigger the cooperating antibody - producing B cells to cooperate to make broadly neutralizing antibodies in a manner that mimics broadly neutralizing antibody development in natural HIV infection.

At the start, researchers pinned their hopes on vaccines designed to trigger production of antibodies against HIV's surface protein.

«We learned in this study that grabbing hold of these glycans can be a very important early step in an effective immune response to HIV, and with this knowledge, we believe we can design better candidate vaccines,» said principal investigator Dennis R. Burton, professor of immunology and microbiology at TSRI.

Defining how to safely replicate these attributes in HIV - uninfected vaccine recipients may lead to better designed experimental vaccines to protect against HIV.

This approach represents a departure from traditional vaccine designs, which have been developed and tested against HIV in vulnerable populations since the mid-1980s without success.

«Results from a former AIDS vaccine study have shown that in a worst case scenario, immunization against HIV could enhance infection,» says Christiane Stahl - Hennig, who designed the project in cooperation with the former DPZ employee Sieghart Sopper.

For 30 years, researchers have struggled to determine which immune responses best foil HIV, information that has guided the design of AIDS vaccines and other prevention approaches.

Researchers at the University of Maryland and Duke University have designed a novel protein - sugar vaccine candidate that, in an animal model, stimulated an immune response against sugars that form a protective shield around HIV.

Wang and collaborators designed a vaccine candidate using an HIV protein fragment linked to a sugar group.

This kind of research — figuring out which of the many HIV strains are affecting local people and how they are transmitted — is essential for designing an effective vaccine.

We believe that HIV controllers can provide key insights for vaccine design.

HIV vaccines are designed to evoke antibody responses.

Dr. Schief's work focuses on computation - guided and structure - based design of immunogens and immunization regimens, with the goal of inducing broadly neutralizing antibodies against HIV and other pathogens that have frustrated traditional vaccine design strategies.

While studying a group of women at risk of HIV in Mombasa, Kenya, Dr. Julie Overbaugh and colleagues found a potential vulnerability in the AIDS virus that could lead to clues for designing an effective vaccine.

Today, about 70 percent of the research under way in Dr. Steinman's laboratory at Rockefeller focuses on designing a vaccine against HIV.

These results may provide new ways for vaccine researchers to target HIV and may influence the design of future HIV vaccines.

Dr. Leo Stamatatos, an immunologist in Fred Hutch's Vaccine and Infectious Disease Division, has received funding from the National Institutes of Health to begin manufacturing an HIV vaccine candidate designed to stimulate the production of broadly neutralizing antibodies and to test the experimental vaccine in human clinical Vaccine and Infectious Disease Division, has received funding from the National Institutes of Health to begin manufacturing an HIV vaccine candidate designed to stimulate the production of broadly neutralizing antibodies and to test the experimental vaccine in human clinical vaccine candidate designed to stimulate the production of broadly neutralizing antibodies and to test the experimental vaccine in human clinical vaccine in human clinical trials.

This approach will also elucidate mechanisms of anti-body mediated protection from infection by HIV - that are highly likely to inform vaccine design.

In Toronto, Pai applies crystallography to gain a more complete understanding of an HIV neutralizing antibody that may help in the design of an HIV vaccine.

Before joining IDRI, Tracey worked as a Protocol Development Manager with the HIV Vaccine Trials Network at the Fred Hutchinson Cancer Research Center where she led multi-disciplinary teams in the design and implementation of clinical trials evaluating candidate HIV and tuberculosis vaccines.

Using enhanced DNA technology, the lab has designed DNA vaccines that drive immune responses in prophylactic or therapeutic settings against Human Immunodeficiency Virus (HIV), Dengue (DV), Chikungunya virus (CHIKV), Middle Eastern Respiratory Syndrome (MERS) virus, and Zika Virus (ZV).

Hundreds of HIV vaccine scientists attending the 2011 Aids Vaccine conference in Bangkok, Thailand have said the stage is now set to design a safe and effective vvaccine scientists attending the 2011 Aids Vaccine conference in Bangkok, Thailand have said the stage is now set to design a safe and effective vVaccine conference in Bangkok, Thailand have said the stage is now set to design a safe and effective vaccinevaccine.

The findings were published In the New England Journal of Medicine (NEJM) and concluded that vaccines designed to induce higher levels of V1V2 antibodies and lower Env - specifc IgA antibodies could result in improved efficacy against HIV - 1 infection.

Researchers are making progress in developing vaccine immunogens designed to induce broadly neutralizing antibodies (bNAbs) against HIV.

The vaccine, designed for testing in Thailand where clade B and recombinant E / A HIV predominates, was found 31 % effective in preventing HIV infection among Thai volunteers.